Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Yamashita Health Care Holdings (TSE:9265) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Yamashita Health Care Holdings Cash Conversion Cycle Related Terms
Yamashita Health Care Holdings Cash Conversion Cycle Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yamashita Health Care Holdings Cash Conversion Cycle Chart
TSE:9265 vs MCK, COR, CAH: Cash Conversion Cycle Comparison
For the Medical Distribution subindustry, Yamashita Health Care Holdings's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yamashita Health Care Holdings Cash Conversion Cycle vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Yamashita Health Care Holdings's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Yamashita Health Care Holdings's Cash Conversion Cycle falls into.
Yamashita Health Care Holdings Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yamashita Health Care Holdings (TSE:9265) has a Cash Conversion Cycle of 37.95 as of Feb. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Yamashita Health Care Holdings and its competitors.
Is Yamashita Health Care Holdings' Cash Conversion Cycle too high?
Yamashita Health Care Holdings' current Cash Conversion Cycle is 37.95. The Medical Distribution industry median Cash Conversion Cycle is 50.89. Yamashita Health Care Holdings' value of 37.95 is 25.4% below this industry median. Overall, Yamashita Health Care Holdings has a GF Score™ of 64/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Yamashita Health Care Holdings' Cash Conversion Cycle compare to MCK and COR?
Yamashita Health Care Holdings' Cash Conversion Cycle of 37.95 can be compared against companies in the Medical Distribution industry. The industry median Cash Conversion Cycle is 50.89. Yamashita Health Care Holdings' value of 37.95 is 25.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Distribution company?
The median Cash Conversion Cycle among Medical Distribution companies is 50.89, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Yamashita Health Care Holdings's current Cash Conversion Cycle of 37.95 is 25.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Yamashita Health Care Holdings and its competitors. For the Medical Distribution industry, the median Cash Conversion Cycle is 50.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yamashita Health Care Holdings's current Cash Conversion Cycle is 37.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yamashita Health Care Holdings stock overvalued right now?
Based on GuruFocus' analysis, Yamashita Health Care Holdings (TSE:9265) is currently considered Modestly Overvalued. The stock's GF Value™ is 円2,955.01, compared to a current price of 円3,400.00 — trading 15.1% above its estimated fair value. The current Cash Conversion Cycle is 37.95 and 25.4% below the Medical Distribution industry median of 50.89. Yamashita Health Care Holdings' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Yamashita Health Care Holdings (TSE:9265), the current Cash Conversion Cycle is 37.95 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Yamashita Health Care Holdings (TSE:9265) Overvalued in 2026?
Based on GuruFocus' analysis, Yamashita Health Care Holdings stock appears to be overvalued.
The current stock price of 円3,400.00 is trading 15.1% above its estimated GF Value™ of 円2,955.01.
GuruFocus considers Yamashita Health Care Holdings to be Modestly Overvalued.
Key valuation signals for TSE:9265:
Cash Conversion Cycle: 37.95
GF Value™: 円2,955.01 vs. price of 円3,400.00 (15.1% above fair value)
Industry Position: 25.4% below the Medical Distribution median
No single metric tells the full story. See the TSE:9265 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Yamashita Health Care Holdings Inc is a Japan-based medical equipment wholesale company that sells medical equipment for medical institutions within the Kyushu area. The company is also engaged in the manufacture, sale, leasing, and rental of optical instruments, physicochemical instruments, analytical instruments, measuring instruments, health equipment, exercise equipment, nursing care equipment, animal medical equipment, and veterinary drugs.
64GF Score
Get the complete analysis for TSE:9265
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:9265 has been successfully added to your 
